<DOC>
	<DOCNO>NCT01230580</DOCNO>
	<brief_summary>The PIVOT trial aim determine whether strategy switch PI monotherapy non-inferior continue triple-therapy , term proportion patient maintain drug treatment option available baseline least 3 year follow-up , compare clinical event , safety , toxicity health economic parameter two strategy .</brief_summary>
	<brief_title>Protease Inhibitor Monotherapy Versus Ongoing Triple-therapy Long Term Management HIV Infection ( PIVOT )</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<criteria>Vl &lt; 50 24 week prior screen CD4 &gt; 100 screen 1 . Known major protease resistance mutation ( ) document prior resistance test perform ( prior resistance test mandatory trial participation ) . 2 . Previous change ART drug regimen reason unsatisfactory virological response ( patient change regimen prevention management toxicity improve regimen convenience permit enter trial ) . 3 . Previous allergic reaction PI . 4 . Patient currently use likely require use concomitant medication know interaction PIs . 5 . Patient require treatment radiotherapy , cytotoxic chemotherapy , anticipate need trial period . 6 . Treatment acute opportunistic infection within 3 month prior trial screening . 7 . Pregnant try become pregnant time trial entry . 8 . History active substance abuse psychiatric illness , opinion investigator , would preclude compliance protocol , dose schedule assessment . 9 . History HIV encephalopathy current deficit &gt; 1 domain Neuropsychiatric AIDS Rating Scale ( see Appendix 7 ) . 10 . Past current history cardiovascular disease , 10 year absolute coronary heart disease risk &gt; 30 % , risk &gt; 20 % patient diabetes family history premature ischaemic heart disease stroke . 11 . History insulindependent diabetes mellitus . 12 . Patient currently receive interferon therapy Hepatitis C virus infection plan start treatment Hepatitis C time trial entry . 13 . Coinfection hepatitis B , define Hepatitis BsAg positive screening time since HIV diagnosis , unless patient document Hepatitis B DNA measurement less 1000 copies/ml take whilst Hepatitis B active drug . 14 . Any active clinically significant condition , finding screen medical history examination , abnormality screen laboratory blood test would , opinion investigator , compromise patient 's safety outcome trial . 15 . Fasting plasma glucose &gt; 7.0mmol/L trial screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Protease Inhibitors</keyword>
	<keyword>RNA virus infection</keyword>
	<keyword>Virus disease</keyword>
	<keyword>Sexually Transmitted Diseases viral</keyword>
	<keyword>Immune system disease</keyword>
	<keyword>Anti-infective Agents</keyword>
	<keyword>Drug resistance</keyword>
</DOC>